近日，知名眼科用药企业莎普爱思（Shapuaisi）再次遭遇股东减持，引发市场关注。据公司公告显示，其持股5%以上的重要股东近期通过集中竞价交易方式减持了部分股份，减持比例虽未触及重大变动阈值，但已是该股东年内第二次减持。市场分析人士指出，此举可能反映出股东对公司未来盈利前景或估值水平的谨慎态度。莎普爱思曾因主打产品“苄达赖氨酸滴眼液”被质疑疗效而陷入舆论风波，尽管公司此后加强了科研投入并拓展多元化产品线，但品牌信任度恢复仍需时间。此次减持消息公布后，公司股价出现小幅下跌，投资者情绪趋于谨慎。值得注意的是，莎普爱思近年来积极布局中成药、化学药及医疗器械领域，试图摆脱对单一产品的依赖。然而，在医药行业监管趋严、集采政策持续推进的背景下，企业转型压力依然较大。股东连续减持虽不必然代表公司基本面恶化，但无疑为投资者敲响了警钟，提示需密切关注其后续经营策略与财务表现。
Recently, Shapuaisi, a well-known ophthalmic pharmaceutical company, has once again faced share sell-offs by major shareholders, drawing market attention. According to the company’s disclosure, a key shareholder holding more than 5% of shares recently reduced its stake through centralized bidding transactions. Although the reduction did not trigger a material change threshold, it marks the second such sale by the same shareholder this year. Market analysts suggest this move may reflect cautious sentiment regarding the company’s future profitability or valuation.Shapuaisi previously faced public controversy over the efficacy of its flagship product—Bendalysine Eye Drops. Despite subsequent efforts to boost R&D investment and diversify its product portfolio, rebuilding brand trust remains an ongoing challenge. Following the announcement of the share reduction, the company’s stock price experienced a modest decline, signaling heightened investor caution.Notably, Shapuaisi has been actively expanding into traditional Chinese medicine, chemical pharmaceuticals, and medical devices in recent years to reduce reliance on a single product. However, under tightening regulatory oversight and the continued rollout of centralized drug procurement policies in China’s pharmaceutical sector, the company still faces significant transformation pressures. While repeated shareholder sell-offs do not necessarily indicate deteriorating fundamentals, they serve as a warning for investors to closely monitor Shapuaisi’s strategic direction and financial performance going forward.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/5357.html